Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.

ABSTRACT:

Context.—

The diagnosis and clinical management of patients with diffuse gliomas (DGs) have evolved rapidly over the past decade with the emergence of molecular biomarkers that are used to classify, stratify risk, and predict treatment response for optimal clinical care.

Objective.—

To develop evidence-based recommendations for informing molecular biomarker testing for pediatric and adult patients with DGs and provide guidance for appropriate laboratory test and biomarker selection for optimal diagnosis, risk stratification, and prediction.

Design.—

The College of American Pathologists convened an expert panel to perform a systematic review of the literature and develop recommendations. A systematic review of literature was conducted to address the overarching questio

SUBMITTER: Brat DJ 

PROVIDER: S-EPMC9311267 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature